Medicare Part D

(s)
8:30 AM
Keynote Address:
KEY SUCCESS FACTORS FOR IMPLEMENTATION OF MEDICARE PART D

While no one can be certain how the MMA is likely to change in the coming years, there are a few possible scenarios to consider. For example, how should pharmaceutical companies establish and build relationships directly with the CMS? Also, what are the prospects for more direct negotiation of prices between the pharmaceutical industry and CMS? This presentation will examine these scenarios and discuss potential preparations pharmaceutical companies can make in anticipation.

Mark McClellan, M.D., Ph.D., Administrator
CENTERS FOR MEDICARE AND MEDICAID SERVICES (INVITED)

(s)
9:15 AM
THE EFFECT OF TRANSITIONING DUAL- ELIGIBLES UNDER MEDICARE PART D

In accordance with the Medicare Modernization Act, on January 1, 2006 approximately 6.4 million dual-eligibles—those qualifying for both Medicaid and Medicare—will shift to Medicare Part D. At the start of the program CMS will automatically enroll dual-eligibles in a Part D drug plan serving their geographic area. The importance of pharmaceutical products to dual-eligibles is significant since many of these patients have the greatest needs and the lowest incomes. With many moving parts, a seamless transition from Medicaid to Medicare poses a number of challenges to ensure that a break in patient care does not occur. This shift will not only affect how patients pay for and receive healthcare benefits, but will also change the way benefits are managed by private program sponsors and paid for at both the State and Federal levels.

This presentation will examine the profile of dual-eligibles, and will discuss the implications of this transition on pharmaceutical companies, managed care organizations, pharmacy benefit managers, and the State and Federal governments.

Kevin Barnett, Senior Vice President, Managed Markets Practice
CAMPBELL ALLIANCE

(s)
9:50 AM
NETWORKING


(s)
10:35 AM
PART D IMPLEMENTATION: PROGRESS AND CHALLENGES

Prospective PDP and MA-PD sponsors have submitted their bids to CMS and will get approval in September to start marketing to Medicare beneficiaries in October. This talk will assess the progress to date and the challenges awaiting us this Fall from a manufacturer's perspective. What impact can we expect in the pharmaceutical market in 2006 as the new drug plans take effect?

S. Lawrence Atkins, Ph.D., Executive Director, Public Policy and
Reimbursement
SCHERING-PLOUGH CORPORATION

(s)
11:10 AM
HOW STRATEGIC PARTNERSHIPS WILL MAKE OR BREAK MCO AND PHARMACEUTICAL COMPANY PROPOSALS

Richard Cook, PharmD, Manager, Clinical and Quality Programs
BLUE CARE NETWORK

(s)
11:45 AM
THE SHIFTING ROLE OF PHARMACY BENEFIT MANAGERS

Some pharmaceutical companies have reduced their emphasis on PBMs, not convinced that PBMs can truly drive commercial business. However, this may change under Medicare Part D, as PBMs are likely to become the foremost administrators of Medicare Prescription Drug Plans (PDPs).

This presentation will discuss how pharmaceutical companies may alter their approaches as PBMs gain the ability to drive Medicare business.

Frederick Howe, President/CEO
MEDIMPACT HEALTHCARE SYSTEMS, INC.

(s)
12:20 PM
LUNCHEON


(s)
1:45 PM
HOW PHARMACEUTICAL COMPANIES CAN EFFECTIVELY COLLABORATE WITH THIRD PARTY PAYORS

The addition of an outpatient pharmacy benefit to the Medicare Program allows all Medicare eligible recipients the opportunity to access pharmaceuticals via various third party payors types, with some familiar payors and potentially new payors expected to provide benefit. Given the current estimate of 40 Million eligible recipients and the future growth of this population, both Medicare and its third party payors will be critically important to the Industry.

This presentation will review the roles of the various third party payors, address the challenges that can impact the Industry's relationship with them, and propose areas for possible collaboration.

Regina Behar, PharmD
Government Regional Medical and Research Specialist
PFIZER, INC

(s)
2:20 PM
THE PSYCHOLOGY OF THE PHYSICIAN AND MEDICARE PART D

In this presentation, Dr. Vanderveer will discuss the ways in which the world of the physician will be impacted by Medicare Part D. Included in his presentation will be a discussion of the impact of Part D on treatment patterns and product selection, for Medicare Patients and non-Medicare patients. He will focus on how pharmaceutical companies will need to modify the “4T’s” (Targeting, Tailoring, Tactical Implementation and Total Customer Satisfaction) of their approach to physicians in the new world of 2006, and will play digital video “footage” of physicians being interviewed on their perspectives on this important topic.

Richard Vanderveer, Ph.D., CEO
V2 GFK

(s)
2:55 PM
THE IMPACT OF MEDICARE PART D ON THE BIOTECHNOLOGY INDUSTRY

This talk will address the overall impact of the legislation on the biotechnology and pharmaceutical industry in terms of physician and hospital payment changes, new delivery systems for both Medicare providers and beneficiaries under CAP and Part D, and impact of the MMA on beneficiaries.

The talk will also address the evolving relationships among stakeholders and the increased role of the federal government in the commercialization of new therapies. The session will focus on the unique challenges and opportunities for biotech products.

Chris Mancill, Associate Director Global Government Affairs
AMGEN, INC.

(s)
3:30 PM
NETWORKING


(s)
4:00 PM
CASE STUDY: IMPACT OF THE MMA ON INTERACTIONS BETWEEN ACCOUNT MANAGERS AND MANAGED CARE CUSTOMERS

As a component of the MMA, Part D will have significant implications for many of the stakeholders involved, including MCOs, PBMs, and pharmaceutical companies. MCOs and PBMs participating in Part D will face various new challenges, such as establishing and managing a Medicare formulary, meeting government requirements, and effectively engaging their Medicare members.

Similarly, pharmaceutical companies will need to adjust their approach to dealing with PBMs and MCOs, accommodating the unique requirements of both the commercial and Medicare businesses of their customers.

This session will discuss the expectations of one another with respect to how the Part D benefit will affect interactions between manufacturers and MCOs and PBMs, and how commercial managed care and Medicare could influence each other’s evolution.

MODERATOR:
Robert Navarro, PharmD, Executive Advisory Group
CAMPBELL ALLIANCE

PANELISTS:

Allan Brooks, Vice President, Public Sector
BRISTOL-MYERS SQUIBB COMPANY

John Driscoll, Senior Vice President of Product & Business Development
MEDCO HEALTH SOLUTIONS, INC.

William Fleming, PharmD, Vice President of Pharmacy Management and
Emerging Technologies
HUMANA (INVITED)

Greg Drew, R.Ph.
Vice President of Pharmacy Health Services
RITE AID CORPORATION

(s)
5:30 PM
NETWORKING RECEPTION & THEME CASINO NIGHT

SPONSORED BY: CAMPBELL ALLIANCE

This evening we’ll take a respite from sessions to have some fun. A networking dinner, buffet style, cocktails and casino games are planned for you and your fellow attendees and speakers to enjoy. Leave your cash at home, the money’s fake. Three prizes will be awarded during the general session the following morning on Tuesday, June 28, 2005 for those who end up with the highest cash at the end of the evening. Come join your colleagues for some fun. The function is open to all attendees and speakers.

NO SEPARATE REGISTRATION REQUIRED

(s)

Tuesday, June 28, 2005 (Day 2) Return to Top

7:15 AM
REGISTRATION, CONTINENTAL BREAKFAST & NETWORKING

SPONSORED BY: COVANCE

(s)
8:00 AM
CHAIR’S REMARKS

Robert Navarro, PharmD, Executive Advisory Group
CAMPBELL ALLIANCE

(s)
8:15 AM
HOW AMERICA CAN AFFORD TO GROW OLDER: A VISION FOR THE FUTURE

John Rother
Director, Policy & Strategy
AARP

(s)
9:00 AM
IMPROVING PRESCRIPTION DRUG ACCESS AND COMPLIANCE INTHE MEDICARE POPULATION

The MMA has the potential to improve compliance and persistence in the Medicare population, offering positive implications for certain pharmaceutical products. However, there is a great deal of confusion in the market that may impede access.

This session will discuss services and programs pharmaceutical companies can put into place to minimize confusion and encourage compliance further. This session will also address ways to alleviate the potential negative impact of the Part D "donut hole" gap in coverage.

Lynn Macilwain
Principal
COVANCE, INC.

(s)
9:30 AM
INCREASING COMPLIANCE UNDER MEDICARE PART D: PHARMACEUTICAL COMPANY PERSPECTIVE

Timothy Klapish, Executive Director, Medical Affairs and Commercial
Operations
GLAXOSMITHKLINE

Terry McInnis, M.D., Medical Director
GLAXOSMITHKLINE

(s)
10:00 AM
NETWORKING


(s)
10:45 AM
IMPACT OF PART D REGIONS ON PHARMACEUTICAL COMPANIES’ COMMERCIAL MANAGED CARE BUSINESS

The implementation of Part D regions throughout the country has virtually redrawn existing competitive boundaries. This could have a massive impact on commercial managed care, particularly for local and regional MCOs. This panel will discuss how the new Part D regions could affect pharmaceutical companies as well as potential strategies to remain competitive. Panelists will include representatives from a pharmaceutical company and an MCO.

MODERATOR:
Robert Navarro, PharmD, Executive Advisory Group
CAMPBELL ALLIANCE

PANELISTS:
Timothy Klapish, Executive Director, Medical Affairs and Commercial
Operations
GLAXOSMITHKLINE

Richard Cook, PharmD, Manager, Clinical and Quality Programs
BLUE CARE NETWORK

Allan Brooks, Vice President, Public Sector
BRISTOL-MYERS SQUIBB COMPANY

G. Lawrence Atkins, Ph.D., Executive Director, Public Policy and
Reimbursement
SCHERING-PLOUGH CORPORATION

Sid Stolz
Senior Vice President, Marketing
CAREMARK RX, INC.

(s)
12:00 PM
LUNCHEON


(s)
1:15 PM
THE EVOLVING ROLE OF HEALTH ECONOMICS AND OUTCOMES RESEARCH UNDER PART D

Health economics and outcomes research have long been tools for pharmaceutical companies to demonstrate the economic value of their products.

This presentation will cover how the use of such data and research may need to differ under Medicare Part D from its traditional uses in commercial managed care.

MODERATOR:
Jan Hansen, Ph.D., Vice President, Sales
NDC HEALTH

PANELISTS:

Jeffrey White, PharmD, M.S., Associate Director - PharmacoEconomics and
Health Outcomes Research
ELAN PHARMACEUTICALS

Diana Brixner, RPh, Ph.D., Associate Professor, Department Chair,
Department of Pharmacotherapy
UNIVERSITY OF UTAH
(FORMERLY Vice President Health Care Management, NOVARTIS)

Brian Luce, Ph.D., MBA, President
MEDTAP

Jayson Slotnik, JD, MPH, Director, Medicare Reimbursement and Economic Policy
BIOTECHNOLOGY INDUSTRY ASSOCIATION (BIO)

(s)
2:30 PM
NETWORKING


(s)
2:45 PM
POTENTIAL IMPACT OF EPRESCRIBING

The MMA will mandate widespread e-prescribing by physicians by 2008. This presentation will discuss how this mandate will be implemented and identify issues and opportunities for pharmaceutical companies.

CO – PRESENTATIONS BY:

Bob Elson, M.D., MS, Vice President of Medical Affairs
RXHUB

Sabrina Allan, Senior Corporate Counsel
PFIZER, INC.

(s)
3:25 PM
IMPLICATIONS FOR PHARMACEUTICAL FIELD SALES

The MMA promises to have a significant affect on pharmaceutical sales forces. As Medicare formularies gain significant mindshare in their respective regions, “spill-over” effects could significantly impact physicians’ prescribing behaviors for Medicare as well as privately covered patients. This may require sales forces to alter their approaches to targeting, territory alignment, incentive compensation, and pull-through.

This presentation will outline why these changes could come about and how pharmaceutical companies can prepare for them.

Garry O Grady, Vice President, Sales Practice
CAMPBELL ALLIANCE

(s)
4:00 PM
SEGMENTATION OF THE SENIOR MARKET AND IMPLICATIONS FOR PHARMACEUTICAL COMPANIES

The senior market for pharmaceuticals is large, complex, and dominated by several specific therapeutic categories.

This presentation will describe how the Medicare population is segmented in terms of age, income, geography, dual-eligibles (Medicare and Medicaid), and current and future sources of prescription coverage. In addition, it will describe how pharmaceutical marketers can use their knowledge of these segments to drive their strategic planning efforts.

CO-PRESENTATIONS BY:

Jeff Kanis, Vice President, Managed Care
NDC HEALTH

Tony Lanzone, Senior Practice Executive, Managed Markets
CAMPBELL ALLIANCE

(s)
4:40 PM
CHAIR’S CLOSING REMARKS


(s)
5:00 PM
CONFERENCE CONCLUDES

Although the Medicare Prescription Drug Benefit will not go into effect until January 1 of next year, pharmaceutical companies faced pressing deadlines at the beginning of 2005 that could significantly affect their share of the business from the 42 million Americans currently eligible for Medicare. April 18, 2005 was the deadline for MCOs, PBMs, and other possible plan administrators to submit their proposed Medicare formularies and approved drugs to CMS. To meet that deadline, MCOs and PBMs were in constant contact with pharmaceutical companies to ask how they planned to contract for their products.

While many pharmaceutical companies were focused on their strategic planning efforts during the first half of 2005, they should not lose sight of the broader ramifications of the benefit. As companies implement their strategies, the selling environment may change significantly, and as a result, some sales and marketing tactics may need to be adjusted. It is difficult to predict exactly what those changes will look like, but it is possible to identify where they are likely to take place.

FEATURED KEYNOTES:

Key Success Factors for the Implementation of Medicare Part D

Mark McClellan, M.D., Ph.D.
Administrator
CENTERS FOR MEDICARE AND MEDICAID SERVICES (INVITED)

How American Can Afford to Grow Older: A Vision for the Future

John Rother
Director of Policy & Strategy